Mesothelioma: Path to Multimodality Treatment

Seminars in Thoracic and Cardiovascular Surgery

Volumn 21, Issue 2, 2009, Pages 125-131

  Su, Stacey ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adjuvant and neoadjuvant chemotherapy; asbestos; diagnosis; extrapleural pneumonectomy; innovative treatments; patient selection; pleurectomy and decortication; radiation therapy; staging

Indexed keywords

ANTHRACYCLINE; ANTIMETABOLITE; BLEOMYCIN; CISPLATIN; DOXYCYCLINE; MITOMYCIN; PEMETREXED; PLATINUM DERIVATIVE; TALC;

ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MALIGNANT MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PATIENT SELECTION; PERITONEUM MESOTHELIOMA; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PROGNOSIS; SURVIVAL TIME; VIRAL GENE THERAPY;

CHEMOTHERAPY, ADJUVANT; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MESOTHELIOMA; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PLEURAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 70349728488     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2009.07.006     Document Type: Article

References (80)

1. Lieutaud J: Historia anatomic-Medica, etc. Paris, 1767, p 86
2. Smith D. The history of mesothelioma. In: Pass H., Vogelzang N., and Carbone M. (Eds). Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies (2005), Springer Verlag, New York, NY 1-20
3. Du Bray E., and Rosson F. Primary mesothelioma of the pleura: A clinical and pathologic contribution to pleural malignancy, with a report of a case. Arch Intern Med 26 (1920) 715-737
4. Stout A., and Murray M.R. Localized pleural mesothelioma. Arch Pathol 34 (1942) 951-964
5. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
6. Selikoff I.J., Churg J., and Hammond E.C. Relation between exposure to asbestos and mesothelioma. N Engl J Med 272 (1965) 560-565
7. Selikoff I.J. Lung cancer and mesothelioma during prospective surveillance of 1249 asbestos insulation workers, 1963-74. Ann NY Acad Sci 271 (1976) 448-456
8. OSHA: Work-Related Lung Disease Surveillance Report 2007: US Department of Health and Human Services, National Institute for Occupational Safety and Health, ed. Cincinnati, OH, 2008
9. Environmental Protection Agency. EPA asbestos materials bans: Clarification (1999) Washington, DC
10. Carbone M., Kratzke R.A., and Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 29 (2002) 2-17
11. Lopez-Rios F., Illei P., Rusch V., et al. Absence of SV40 DNA and RNA in human pleural mesotheliomas: High risk of false positive DNA results with use of primers prone to amplify SV40 sequences present in common laboratory plasmids. Mod Pathol 17 suppl 1 (2004) 340A
12. Pancaldi C., Balatti V., Guaschino R., et al. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Infect 58 (2009) 53-60
13. Renshaw A.A., Dean B.R., Antman K.H., et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111 (1997) 106-109
14. Boutin C., Rey F., Gouvernet J., et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72 (1993) 394-404
15. Boutin C., Loddenkemper R., and Astoul P. Diagnostic and therapeutic thoracoscopy: Techniques and indications in pulmonary medicine. Tuber Lung Dis 74 (1993) 225-239
16. Butchart E.G., Ashcroft T., Barnsley W.C., et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31 (1976) 15-24
17. Jaklitsch M., Wiener D., Bueno R., et al. The development of the Brigham and Women's multimodality treatment plan for malignant pleural mesothelioma: A model for improving the treatment of rare diseases. In: Pass H., Vogelzang N., and Carbone M. (Eds). Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies (2005), Springer, New York, NY 696-722
18. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
19. Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111:815-825, discussion, 825-826
20. Sugarbaker D.J., Mentzer S.J., DeCamp M., et al. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 103 (1993) 377S-381S
21. Sugarbaker D.J., Strauss G.M., Lynch T.J., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (1993) 1172-1178
22. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-63 discussion, 63-65
23. Tsao A.S., Wistuba I., Roth J.A., et al. Malignant pleural mesothelioma. J Clin Oncol 27 (2009) 2081-2090
24. Kindler H.L., Belani C.P., Herndon II J.E., et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC # 626715) with or without leucovorin rescue for malignant mesothelioma. Sequential Phase I trials by the Cancer and Leukemia Group B. Cancer 86 (1999) 1985-1991
25. Solheim O.P., Saeter G., Finnanger A.M., et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A Phase I study. Br J Cancer 65 (1992) 956-960
26. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
27. Zidar B.L., Green S., Pierce H.I., et al. A Phase I evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 6 (1988) 223-226
28. Pennucci M.C., Ardizzoni A., Pronzato P., et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: A Phase I FONICAP trial. Italian Lung Cancer Task Force. Cancer 79 (1997) 1897-1902
29. Samson M.K., Wasser L.P., Borden E.C., et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus cyclophosphamide and Adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma InterGroup study. J Clin Oncol 5 (1987) 86-91
30. Samuels B.L., Herndon II J.E., Harmon D.C., et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A Phase I study by the Cancer and Leukemia Group B. Cancer 82 (1998) 1578-1584
31. Dirix L.Y., van Meerbeeck J., Schrijvers D., et al. A Phase I trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5 (1994) 653-655
32. Carmichael J., Cantwell B.M., and Harris A.L. A Phase I trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 25 (1989) 911-912
33. Alberts A.S., Falkson G., Goedhals L., et al. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6 (1988) 527-535
34. Law M.R., Gregor A., Hodson M.E., et al. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax 39 (1984) 255-259
35. Ruffie P., Feld R., Minkin S., et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 7 (1989) 1157-1168
36. Rusch V.W. Trials in malignant mesothelioma. LCSG 851 and 882. Chest 106 (1994) 359S-362S
37. Rusch V.W., Figlin R., Godwin D., et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group Trial. J Clin Oncol 9 (1991) 313-319
38. Rusch V.W., and Venkatraman E.S. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68 (1999) 1799-1804
39. Pass H.I., Kranda K., Temeck B.K., et al. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol 4 (1997) 215-222
40. Flores R.M., Pass H.I., Seshan V.E., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg 135 (2008) 620-626
41. Rice T.W., Adelstein D.J., Kirby T.J., et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 58 (1994) 24-29
42. Rusch V.W. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9 (1997) 367-372
43. Shiraishi Y., Nakajima Y., Koyama A., et al. Morbidity and mortality after 94 extrapleural pneumonectomies for empyema. Ann Thorac Surg 70 (2000) 1202-1206 discussion, 1206-1207
44. Worn H. (Chances and results of surgery of malignant mesothelioma of the pleura (author's transl)). Thoraxchir Vask Chir 22 (1974) 391-393
45. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A Phase I trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
46. Baldini E.H., Recht A., Strauss G.M., et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (1997) 334-338
47. Lee T.T., Everett D.L., Shu H.K., et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124 (2002) 1183-1189
48. Flores R.M., Routledge T., Seshan V.E., et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 136 (2008) 605-610
49. Sugarbaker D.J., and Grondin S.C. Techniques of pneumonectomy. Pleural pneumonectomy. Chest Surg Clin North Am 9 (1999) 379-392 xi
50. Sugarbaker D.J., Heher E.C., Lee T.H., et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 102 (1991) 10-14 discussion, 14-15
51. Sugarbaker D.J., Garcia J.P., Richards W.G., et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224 (1996) 288-294 discussion, 294-296
52. Antman K.H., Blum R.H., Greenberger J.S., et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68 (1980) 356-362
53. Cibas E.S., Corson J.M., and Pinkus G.S. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: The role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol 18 (1987) 67-74
54. Montag A.G., Pinkus G.S., and Corson J.M. Keratin protein immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesothelioma: An immunoperoxidase study of 30 cases. Hum Pathol 19 (1988) 336-342
55. O'Hara C.J., Corson J.M., Pinkus G.S., et al. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 136 (1990) 421-428
56. Sugarbaker D.J., Jaklitsch M.T., Bueno R., et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128 (2004) 138-146
57. Dedrick R.L., Myers C.E., Bungay P.M., et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62 (1978) 1-11
58. Markman M., and Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118 (1992) 547-550
59. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
60. Rusch V.W., Niedzwiecki D., Tao Y., et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies. J Clin Oncol 10 (1992) 1001-1006
61. Carroll N., Mohamed F., and Sugarbaker P. Hyperthermic chemoperfusion, and postoperative chemotherapy: The National Cancer Institute and Washington Hospital Center experience. In: Pass H., Vogelzang N., and Carbone M. (Eds). Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapies (2005), Springer, New York, NY 732-754
62. Wagmiller J., Koehan M., Chabot J., et al. Peritoneal mesothelioma: The Columbia experience. In: Pass H., Vogelzang N., and Carbone M. (Eds) (2005), Springer, New York, NY 723-731
63. Sauter E.R., Langer C., Coia L.R., et al. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 60 (1995) 100-105
64. Colleoni M., Sartori F., Calabro F., et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 82 (1996) 53-56
65. Chang M.Y., and Sugarbaker D.J. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: Techniques and complications. Thorac Surg Clin 14 (2004) 523-530
66. Chang M.Y., and Sugarbaker D.J. Innovative therapies: Intraoperative intracavitary chemotherapy. Thorac Surg Clin 14 (2004) 549-556
67. Janne P.A., and Baldini E.H. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin 14 (2004) 567-573
68. Mujoomdar A.A., and Sugarbaker D.J. Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 20 (2008) 298-304
69. Zellos L., Richards W.G., Capalbo L., et al. A Phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 137 (2009) 453-458
70. Weder W., Kestenholz P., Taverna C., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 (2004) 3451-3457
71. Krug L.M., Pass H.I., Rusch V.W., et al. Multicenter Phase I trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27 (2009) 3007-3013
72. Albelda S.M. Gene therapy for lung cancer and mesothelioma. Chest 111 (1997) 144S-149S
73. Pass H.I., Temeck B.K., Kranda K., et al. Phase II randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 4 (1997) 628-633
74. Sterman D.H., Treat J., Litzky L.A., et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a Phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9 (1998) 1083-1092
75. Zellos L.S., and Sugarbaker D.J. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 29 (2002) 41-50
76. Pass H.I., DeLaney T.F., Tochner Z., et al. Intrapleural photodynamic therapy: Results of a Phase I trial. Ann Surg Oncol 1 (1994) 28-37
77. Castagneto B., Zai S., Mutti L., et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a Phase I study on 31 consecutive patients. Lung Cancer 31 (2001) 303-310
78. Schouwink H., Rutgers E.T., van der Sijp J., et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: Dose finding and toxicity results. Chest 120 (2001) 1167-1174
79. Friedberg J.S., Mick R., Stevenson J.P., et al. Phase I trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 22 (2004) 2192-2201
80. Gordon G.J., Rockwell G.N., Godfrey P.A., et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 4406-4414